HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
28 hedge funds and large institutions have $6.79M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 10 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
17% more capital invested
Capital invested by funds: $5.79M → $6.79M (+$998K)
15% less funds holding
Funds holding: 33 → 28 (-5)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$325K |
| 2 |
BlackRock
New York
|
+$92.9K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$70.2K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$34.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
-$1.45M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$423K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$323K |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$113K |
| 5 |
First Manhattan
New York
|
-$53K |
HTGM Hedge Fund Activity: Q2 2020 in Review
28 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2020, worth a combined $6.79M — up 17% from $5.79M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HTGM and 6 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $325K. The largest seller was Cowen Prime Advisors, exiting entirely with an estimated $1.45M sold.
- 28 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2020, down from 33 in Q1 2020.
- Funds reported $6.79M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2020, up 17% quarter-over-quarter.
- 6 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2020 and 10 closed out, a net change of -4 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2020 was Renaissance Technologies, an estimated $325K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2020 was Cowen Prime Advisors, an estimated $1.45M sold.
Based on aggregated 13F filings for Q2 2020.